XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q3)Sep 30, 2024 | |
---|---|---|
Assets | ||
Current assets | ||
Cash, cash equivalents and short term investments | --1M | --108.63K |
-Cash and cash equivalents | --1M | --108.63K |
Prepaid assets | --323.01K | ---- |
Current deferred assets | ---- | --160.97K |
Total current assets | --1.33M | --269.6K |
Non current assets | ||
Other non current assets | --233.17M | ---- |
Total non current assets | --233.17M | --0 |
Total assets | --234.49M | --269.6K |
Liabilities | ||
Current liabilities | ||
Payables | --22.03K | ---- |
-accounts payable | --22.03K | ---- |
Current accrued expenses | ---- | --73.52K |
Current debt and capital lease obligation | ---- | --178.33K |
-Current debt | ---- | --178.33K |
Current liabilities | --22.03K | --251.85K |
Non current liabilities | ||
Total non current liabilities | --0 | --0 |
Total liabilities | --22.03K | --251.85K |
Shareholders'equity | ||
Share capital | --233.17M | --616 |
-common stock | --233.17M | --616 |
-Preferred stock | --0 | --0 |
Retained earnings | --1.3M | ---8.92K |
Paid-in capital | ---- | --26.05K |
Total stockholders'equity | --234.47M | --17.75K |
Total equity | --234.47M | --17.75K |
Currency Unit | USD | USD |
Accounting Standards | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- |